Secondary Logo

Journal Logo

Breakthrough Therapy Designation for Multiple Myeloma

doi: 10.1097/01.COT.0000499620.22609.5d
FDA Updates
Free
FDA

FDA

The FDA has granted a breakthrough therapy designation to the immunotherapy Darzalex (daratumumab) in combination with lenalidomide (an immunomodulatory agent) and dexamethasone, or bortezomib (a proteasome inhibitor) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

This marks the second time daratumumab has received a breakthrough therapy designation, which is intended to expedite the development and review timelines of potential new medicines to treat serious or life-threatening diseases, where preliminary clinical evidence shows the medicine may provide substantial improvement over existing therapies.

Breakthrough therapy designation was granted to daratumumab based on data from two phase III studies:

  • The MMY3004 (CASTOR) clinical trial evaluating daratumumab in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone, in patients with multiple myeloma who received at least one prior therapy. Overall, the daratumumab combination therapy demonstrated a reduction in the risk of disease progression or death. These results were presented at the 2016 ASCO Annual Meeting (Abstract LBA4).
  • The MMY3003 (POLLUX) clinical trial evaluating daratumumab in combination with lenalidomide and dexamethasone, compared to lenalidomide and dexamethasone alone, in patients with multiple myeloma who received at least one prior therapy. Overall, the addition of daratumumab reduced the risk of disease progression or death in these patients. These results were presented at the Annual Congress of the European Hematology Association in June 2016 (Abstract LB2238).

“Despite tremendous progress in the past 15 years, multiple myeloma remains a highly complex and difficult disease to treat, with most patients relapsing or becoming resistant to therapy,” said MMY3003 (POLLUX) lead study author Meletios A. Dimopoulos, MD, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece. “Daratumumab has already shown pronounced activity as a monotherapy in heavily pre-treated patients. This designation underscores the potential of daratumumab in combination with either a proteasome inhibitor or an immunomodulatory agent to provide much-needed benefit to patients with at least one prior therapy.”

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!